Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 5/20 | 1.00 |
| ▸ | MAPT | P10636 | 5/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 4/20 | 1.00 |
| ▸ | SLCO1B3 | Q9NPD5 | 4/20 | 1.00 |
| ▸ | SLCO1B1 | Q9Y6L6 | 4/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 4/20 | 1.00 |
| ▸ | SLCO2B1 | O94956 | 3/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | HPGD | P15428 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | ALOX12 | P18054 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | GAA | P10253 | 2/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 2/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | F2 | P00734 | 1/20 | 1.00 |
| ▸ | PLAU | P00749 | 1/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Isosilybin A SCHEMBL972938 | 1.00 | CYP3A4 (1.00) | CYP3A4MAPTCYP2C9SLCO1B3SLCO1B1 | |
| Isosilybin A SCHEMBL18089487 | 1.00 | CYP3A4 (1.00) | CYP3A4MAPTCYP2C9SLCO1B3SLCO1B1 | |
| Silybin B SCHEMBL751461 | 1.00 | CYP3A4 (1.00) | CYP3A4MAPTCYP2C9SLCO1B3SLCO1B1 | |
| Silybin A SCHEMBL23466786 | 1.00 | CYP3A4 (1.00) | CYP3A4MAPTCYP2C9SLCO1B3SLCO1B1 | |
| Silybin A SCHEMBL324884 | 1.00 | CYP3A4 (1.00) | CYP3A4MAPTCYP2C9SLCO1B3SLCO1B1 | |
| Silibinin SCHEMBL24236664 | 1.00 | CYP3A4 (1.00) | CYP3A4MAPTCYP2C9SLCO1B3SLCO1B1 | |
| Silibinin SCHEMBL19194836 | 1.00 | CYP3A4 (1.00) | CYP3A4MAPTCYP2C9SLCO1B3SLCO1B1 | |
| Silibinin SCHEMBL22993978 | 1.00 | CYP3A4 (1.00) | CYP3A4MAPTCYP2C9SLCO1B3SLCO1B1 | |
| Silibinin SCHEMBL22398934 | 1.00 | CYP3A4 (1.00) | CYP3A4MAPTCYP2C9SLCO1B3SLCO1B1 | |
| Isosilybin A SCHEMBL4653986 | 1.00 | CYP3A4 (1.00) | CYP3A4MAPTCYP2C9SLCO1B3SLCO1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 303 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240315965-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2024-09-26 | — | — | US | claimed |
| CN-113197877-B | Pharmaceutical composition comprising silymarin | 海南普利制药股份有限公司 | 2022-11-11 | — | — | CN | claimed |
| WO-2022182527-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2022-09-01 | — | — | WO | claimed |
| CN-109170365-A | A kind of functional feedstuff additive and its application method of cultured fishes liver protecting | 广东渔夫宝水产科技有限公司 | 2019-01-11 | — | — | CN | claimed |
| WO-2013067543-A1 | METHODS AND COMPOSITIONS FOR ADMINISTERING A SPECIFIC WAVELENGTH PHOTOTHERAPY | FOLLEA INTERNATIONAL LTD. (CN) | 2013-05-10 | — | — | WO | claimed |
| US-20130115180-A1 | Methods And Compositions For Administering A Specific Wavelength Phototherapy | APPLIED BIOLOGY, INC. | 2013-05-09 | — | — | US | claimed |
| CN-101129188-B | Legalon mastication patch and method of preparing the same | YANGTZE RIVER PHARM GROUP CO | 2012-07-04 | — | — | CN | claimed |
| CN-100375617-C | Liquid capsule and production method thereof | MINHUA FAN (CN) | 2008-03-19 | — | — | CN | claimed |
| CN-122081128-A | Lactobacillus rhamnosus and application thereof | — | 2026-05-26 | — | — | CN | disclosed |
| US-12637513-B2 | Method of treating cancer by administering an inhibitor of erythropoietin receptor activity comprising either erythropoietin receptor or erythropoietin protein | IMMUNEDGE, INC. (US) | 2026-05-26 | — | — | US | disclosed |
| US-12624118-B2 | Trispecific binding molecules against BCMA and uses thereof | NOVARTIS AG (CH) | 2026-05-12 | — | — | US | disclosed |
| US-20260116986-A1 | EPO RECEPTOR AGONISTS AND ANTAGONISTS | IMMUNEDGE INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-20260035473-A1 | BINDING MOLECULES AGAINST BCMA AND USES THEREOFPrivate view | NOVARTIS AG (CH) | 2026-02-05 | — | — | US | disclosed |
| US-20260034152-A1 | Influx Vitamins and Drinks, with Zinc Ionophoric Influx | BLACK STEPHEN (US) | 2026-02-05 | — | — | US | disclosed |
| CN-1615844-A | Development of micro particle silybum marianum preparation | DONG SHIWEN (CN) | 2005-05-18 | — | — | CN | disclosed |
| CN-1572293-A | A silymarin soft capsule and its preparation method | SHANDONG LUYE NATURAL DRUG R & (CN) | 2005-02-02 | — | — | CN | disclosed |
| CN-1568942-A | Liquid capsule and production method thereof | FAN MINHUA (CN) | 2005-01-26 | — | — | CN | disclosed |
| CN-1513444-A | Medicine for treating metaboic syndrome | 辽宁医联新药研究所 | 2004-07-21 | — | — | CN | disclosed |
| US-5196448-A | Applying silybin derivative to skin | STIEFEL LABORATORIES, INC. (US) | 1993-03-23 | — | — | US | disclosed |
| US-3997671-A | LIVER DISORDERS | DR. MADAUS & CO. (DT) | 1976-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260035473-A1 | BINDING MOLECULES AGAINST BCMA AND USES THEREOFPrivate view | BCL9, BRCA1, VCAM1 | CYP3A4 1775/4885MAPT 1709/4885CYP2C9 605/4885 |
| US-12624118-B2 | Trispecific binding molecules against BCMA and uses thereof | CD2, CD40, CD22 | CYP3A4 1264/4885MAPT 1085/4885CYP2C9 1667/4885 |
| US-12637513-B2 | Method of treating cancer by administering an inhibitor of erythropoietin receptor activity comprising either erythropoietin receptor or erythropoietin protein | EPOR, MPL, CSF3R | CYP3A4 4515/4885MAPT 4634/4885CYP2C9 4284/4885 |
| US-20260034152-A1 | Influx Vitamins and Drinks, with Zinc Ionophoric Influx | KCNN3, VDR, KCNN2 | CYP3A4 2029/4885MAPT 3544/4885CYP2C9 2675/4885 |
| US-20260116986-A1 | EPO RECEPTOR AGONISTS AND ANTAGONISTS | EPOR, STAT5A, JAK2 | CYP3A4 4330/4885MAPT 4701/4885CYP2C9 4206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.